Patient characteristics.
| Characteristic | All Patients, n = 16 |
|---|---|
| Female, n (%) | 13 (81) |
| Age, yrs, mean ± SD | 52.9 ± 12.7 |
| Ethnicity, n (%) | |
| Latino/Hispanic | 8 (50) |
| Asian/Pacific Islander | 3 (19) |
| White | 5 (31) |
| Disease duration, yrs, mean ± SD | 7.7 ± 7.6 |
| DAS28-ESR*, mean ± SD | 3.5 ± 1.6 |
| DAS28-CRP*, mean ± SD | 3.3 ± 1.4 |
| ESR, mm/h, mean ± SD | 24.8 ± 26.6 |
| CRP, mg/l, mean ± SD | 4.8 ± 5.4 |
| Rheumatoid factor-positive, n (%) | 13 (81) |
| Anti-CCP-positive, n (%) | 13 (81) |
| DMARD†, n (%) | 15 (94) |
| Methotrexate, n (%) | 12 (75) |
| Prednisone, n (%) | 10 (63) |
| Anti-tumor necrosis factor, n (%) | 6 (38) |
↵* Disease Activity Score 28 (DAS28) is calculated using tender and swollen joint counts, patient global visual analog scale, and erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP).
↵† Disease-modifying antirheumatic drugs (DMARD) include any DMARD other than prednisone (i.e., methotrexate, plaquenil, sulfasalazine, azathioprine, leflunomide, anti-tumor necrosis factor-α medications, and rituximab). CCP: cyclic citrullinated peptide.